Description

Rimantadine-Darnitsa (rimantadine hydrochloride) tablets 0.05 g. №20

Ingredients

Active ingredient: Rimantadine hydrochloride 0.05 g per tablet.

Dosage

Dosage: The usual adult dose is 100 mg twice daily. Consult a healthcare professional for appropriate dosing.

Indications

Indications: Rimantadine-Darnitsa is indicated for the prophylaxis and treatment of influenza A virus infections.

Contraindications

Contraindications: Do not use Rimantadine-Darnitsa if allergic to rimantadine or any other ingredients in the product.

Directions

Directions: Take Rimantadine-Darnitsa as directed by your healthcare provider. Do not exceed the recommended dosage.

Scientific Evidence

Rimantadine hydrochloride, the active ingredient in Rimantadine-Darnitsa, is a viral replication inhibitor that works by blocking the ion channel of the influenza A virus. Studies have shown that rimantadine is effective in reducing the severity and duration of influenza symptoms when taken within 48 hours of symptom onset.

Additional Information

Rimantadine-Darnitsa is well-tolerated, with common side effects including nausea and dizziness. It is important to complete the full course of treatment as prescribed to ensure maximum effectiveness.

Pharmacological Effects: Rimantadine-Darnitsa exerts its antiviral effects by interfering with the replication of the influenza A virus. By inhibiting the virus’s ion channel, rimantadine prevents the release of viral genetic material into the host cell, thereby reducing viral replication and spread.

Clinical Trials: Clinical trials have demonstrated the efficacy of rimantadine in both the prophylaxis and treatment of influenza A infections. A study published in the Journal of Infectious Diseases showed that rimantadine significantly reduced the duration of illness and viral shedding in patients with confirmed influenza A virus infections.